ArticleNeuro-oncology advances
Impact of Bevacizumab treatment intervals on surgical interventions in pediatric neuro-oncology.
Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Bevacizumab (BVZ) is widely used in patients with central nervous system (CNS) tumors. Due to its potential to impair wound healing, a minimum interval of 28 days between BVZ administration and surgery - both before and after the procedure - is generally recommended. However, strict adherence to this interval is often challenging in clinical practice, particularly when urgent oncologic treatment or time-sensitive surgical interventions are required. Methods: Pediatric patients with a CNS tumor receiving intravenous BVZ from January 2005 to December 2022 treated at the Medical University of Vienna were retrospectively analyzed for surgical complications. Results: One hundred and nineteen patients had 344 surgeries with BVZ therapy before and or after surgery. 11 wound complications (3.20%) of any grade ( Conclusion: BVZ can be administered within ≤ 28 days before or after surgery when postponing the procedure is not feasible or when immediate (re)initiation of therapy is required, provided that non-absorbable sutures are used, and close wound-monitoring is ensured.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.